Overview

Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas

Status:
Terminated
Trial end date:
2019-07-17
Target enrollment:
Participant gender:
Summary
This is a phase 3, multicenter, open-label, sponsor blinded, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability of intravenous murepavadin given with ertapenem versus an anti-pseudomonal β-lactam based antibiotic in the treatment of nosocomial pneumonia in adult subjects
Phase:
Phase 3
Details
Lead Sponsor:
Polyphor Ltd.
Treatments:
Anti-Bacterial Agents
Antibiotics, Antitubercular
beta-Lactams
Ertapenem
Murepavadin
Piperacillin, tazobactam drug combination